摘要:
Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.
摘要:
Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.
摘要:
The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.
摘要:
The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要:
5-Arylidene-4-oxo-2-thioxo-3-thiazolidinecarboxylic acids of formula I in which the symbols R1, R2, A, A1 and A2 have the significance given in the description as medicaments for the treatment of cancer diseases.
摘要:
Compounds of formula I, useful as matrix metalloprotease inhibitors, wherein X, Y and Z are each oxygen; R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen; R2 and R3 are each hydrogen; and R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C1-C6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl and cyano.
摘要:
Compounds of formula I, useful as matrix metalloprotease inhibitors, ##STR1## wherein X, Y and Z are each oxygen;R.sub.1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of --NH.sub.2, --NO.sub.2, --SO.sub.2 NH.sub.2, --SO.sub.2 CH.sub.3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen;R.sub.2 and R.sub.3 are each hydrogen; andR.sub.4 and R.sub.5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C.sub.1 -C.sub.6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, --NH.sub.2, --NO.sub.2, --SO.sub.2 NH.sub.2, --SO.sub.2 CH.sub.3, acetyl and cyano.
摘要:
Enzyme specific for bilirubin which has a phenol oxidase activity of less than 0.5% and an activity for biliverdin of less than 10%, a broad pH optimum as well as a good thermostability. The enzyme is obtainable from plants such as alfalfa and is suitable for the determination as well as for the degradation of bilirubin in particular in biological liquids.
摘要:
The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps:—performing a first polymerase chain reaction with three to six 5′-primer and one 3′-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5′-primer and one 3′-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.
摘要:
A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.